Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for INB-200 in Glioblastoma. The expected timing is based on the latest available company guidance and may change.
9/4/24- Continue to monitor patients for long-term remissions. 6/2/25- Presented positive Ph1 data at ASCO '25. 6/9/25- Announces patient achieved 4-yrs in remission. Present updated data at SNO'25 on November 19-23, 2025. 01/12/26:- Updated Ph1 GBM data show improved PFS and OS vs SOC with durable responses and favorable safety. 03/12/26:- GBM Ph1 DeltEx data show mPFS 13 months. Final mOS data expected Mid-2026. 05/06/26:- Phase 1 GBM data to be presented at ASCO on June 1, 2026. 05/07/26:- Reiterated ASCO 2026 GBM mOS update June 1 and planned Phase 1 INB-200 journal publication. 05/14/26:- ISCT/ASGCT 2026 translational analyses support multidose DeltEx DRI benefit. ASCO June 1, 2026 mOS update upcoming. 06/01/26:- Updated Ph1 data at ASCO 2026: mPFS 13.0 months; mOS not reached. 08/06/26:- JCO Ph1 data published. ASCO data reiterated. FDA discussions and additional GBM updates pending.
Verification
Confirm timing and program details against the company announcement or filing.